We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
Boehringer Ingelheim and Eli Lilly and Company announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) ...